{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:01:48Z","timestamp":1790139708348,"version":"4.0.1"},"reference-count":18,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,11,5]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Plasma cell neoplasms may exhibit variations in morphology and immunophenotype, which can mimic mature B-cell lymphoproliferative disorders and pose diagnostic challenges. This case illustrates a rare entity of plasma cell myeloma, where the entire plasma cell population exhibited lymphoid morphology, negativity for CD138, positivity for CD20 and cyclin D1, and positive fluorescence in situ hybridisation for t(11;14) and del(17\u2009p), mimicking a mature B-cell lymphoproliferative disorder, in particular mantle cell lymphoma. In this case, a careful analysis of flow cytometry gating strategies and use of other ancillary tests were keys for correct diagnosis. In addition to the diagnostic implications due to its rarity, CD138-negative plasma cell myeloma may represent a unique entity, which is associated with \u2018stem cell\u2019-like clonogenic properties, more aggressive clinical behaviour and resistance to chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2019-232233","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T05:41:42Z","timestamp":1575265302000},"page":"e232233","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["CD138-negative plasma cell myeloma: a diagnostic challenge and a unique entity"],"prefix":"10.1136","volume":"12","author":[{"given":"Audi Francesca","family":"Setiadi","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sheikine","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"key":"2025082622495942000_12.11.e232233.1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.80"},{"key":"2025082622495942000_12.11.e232233.2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.373"},{"key":"2025082622495942000_12.11.e232233.3","first-page":"1","article-title":"Clinical and biological significance of surface molecules in myeloma","volume":"4","author":"Kawano","year":"2014","journal-title":"Int J Myeloma"},{"key":"2025082622495942000_12.11.e232233.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-436220"},{"key":"2025082622495942000_12.11.e232233.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3096"},{"key":"2025082622495942000_12.11.e232233.6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol"},{"key":"2025082622495942000_12.11.e232233.7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2017.320","article-title":"Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials","volume":"32","author":"Arana","year":"2018","journal-title":"Leukemia"},{"key":"2025082622495942000_12.11.e232233.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.06.016"},{"key":"2025082622495942000_12.11.e232233.9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bbmt.2015.12.030","article-title":"Targeting CD138-\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable Antimyeloma immunity","volume":"22","author":"Lum","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025082622495942000_12.11.e232233.10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1145"},{"key":"2025082622495942000_12.11.e232233.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482919"},{"key":"2025082622495942000_12.11.e232233.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012487","article-title":"Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms","volume":"5","author":"Brennan","year":"2010","journal-title":"PLoS One"},{"key":"2025082622495942000_12.11.e232233.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"de Mel","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025082622495942000_12.11.e232233.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410"},{"key":"2025082622495942000_12.11.e232233.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61188"},{"key":"2025082622495942000_12.11.e232233.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.020"},{"key":"2025082622495942000_12.11.e232233.17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3960\/jslrt.55.137","article-title":"Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5","volume":"55","author":"Yokoi","year":"2015","journal-title":"J Clin Exp Hematop"},{"key":"2025082622495942000_12.11.e232233.18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019001845","article-title":"CD138\u2212 plasma cell myeloma","volume":"134","author":"Shuai","year":"2019","journal-title":"Blood"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:50:09Z","timestamp":1756273809000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,12,1]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bcr-2019-232233"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232233","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}